TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group, Inc.

Cellix Bio is a drug discovery and development company that utilizes augmented intelligence and proprietary platform technology, Synergix AI, to accelerate the drug discovery process. Self-described as innovative, it aims to reduce the time and cost of developing new medicines.

Cellix Bio

NeoChord is a medical technology company that provides a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation, aimed at restoring normal mitral valve function.

NeoChord

NxStage provides home and in-center hemodialysis solutions for patients with chronic kidney disease. The company self-describes its services to improve health outcomes through more frequent dialysis.

NxStage

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group, Inc. Common Stock

Transmedics develops and offers medical technology products that focus on organ transplantation, specifically through the Organ Care System.

Metric
Company Name	TransMedics Group, Inc.	Cellix Bio	NeoChord	NxStage
Symbol	TMDX
MSH ID	COM:TRANSMEDICS	COM:CELLIXBIO	COM:NEOCHORD	COM:NXSTAGE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Devices	Biotechnology	Medical Devices	Medical Devices
Country	US	US	US	US
Stage
Employee Count	584
Website	transmedics.com	cellixbio.com	neochord.com	nxstage.com
LinkedIn
Founders

Metric
Market Cap	4.56B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	241.62M
Revenue (LTM)
Revenue (NTM)
Gross Profit	153.99M
EBITDA	8.76M
Operating Income	485K
Net Income	-25.03M
EPS	-0.77
Diluted EPS	-0.77
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.64
Operating Profit Margin	-0.00
EBITDA Margin	0.04
Net Profit Margin	0.01
Return on Equity	0.02
Return on Assets	0.00
Return on Capital Employed	-0.00

COM:TRANSMEDICS

Transmedics

Last Close

79.34

22/11 21:00

Market Cap

2.14B

Beta: -

Volume Today

2.60M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-79.07
P/B Ratio	22.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	17.60
EV Multiple	3.76K

Metric
Days Sales Outstanding	115.41
Days Payables Outstanding	72.13
Days Inventory Outstanding	184.46
Operating Cycle	280.50
Cash Conversion Cycle	229.17
Asset Turnover	0.47

Metric
Operating Cash Flow	-13.03M
Free Cash Flow	-192.09M
Cash Flow to Debt	0.05
Operating Cash Flow/Sales	0.07
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	394.81M
Accounts Receivable	-33.82M
Inventory	44.23M
Goodwill	11.99M
Debt to Capitalization	0.79
Debt to Assets	0.75
Current Ratio	10.93
Quick Ratio	8.76

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.30
SG&A to Revenue	0.29